Strategic assessment for nonclinical safety in drug discovery

Folia Pharmacologica Japonica ◽

10.1254/fpj.20009 ◽

2020 ◽

Vol 155 (4) ◽

pp. 248-252

Author(s):

Akinobu Okada

Keyword(s):

Drug Discovery ◽

Strategic Assessment

Download Full-text

Epigenetics for Drug Discovery

10.1039/9781782628484 ◽

2015 ◽

Keyword(s):

Download Full-text

Drug Discovery for Leishmaniasis

10.1039/9781788010177 ◽

2017 ◽

Keyword(s):

Download Full-text

Artificial Intelligence in Drug Discovery

10.1039/9781788016841 ◽

2020 ◽

Keyword(s):

Artificial Intelligence ◽

Download Full-text

Phenotypic Drug Discovery

10.1039/9781839160721 ◽

2020 ◽

Keyword(s):

Download Full-text

Drug Discovery from Natural Products

10.1039/9781849734950 ◽

2012 ◽

Keyword(s):

Natural Products ◽

Download Full-text

Ethnomedicine and Drug Discovery

10.1016/s1572-557x(02)x8007-6 ◽

2002 ◽

Keyword(s):

Download Full-text

Bioinformatics and Computational Biology in Drug Discovery and Development

10.1017/cbo9780511989421 ◽

2016 ◽

Keyword(s):

Drug Discovery ◽

Computational Biology ◽

Drug Discovery And Development

Download Full-text

Mass Ligand-Binding Screening Strategies for Identification of Leads for New Drug Discovery

PsycEXTRA Dataset ◽

10.1037/e495942006-003 ◽

1993 ◽

Author(s):

Ronald M. Burch ◽

Keyword(s):

Drug Discovery ◽

Ligand Binding ◽

New Drug ◽

Screening Strategies

Download Full-text

Translating Cognition from the Field to the Clinic in Drug Discovery

PsycEXTRA Dataset ◽

10.1037/e598092013-075 ◽

2011 ◽

Author(s):

Daniela Brunner

Keyword(s):

Download Full-text

Use of mass spectrometric approaches to tackle challenges in drug discovery: The beta-amyloid paradigm

PsycEXTRA Dataset ◽

10.1037/e645292013-002 ◽

2013 ◽

Author(s):

Anthony Tsarbopoulos

Keyword(s):

Drug Discovery ◽

Beta Amyloid ◽

Mass Spectrometric

Download Full-text